Oramed Pharmaceuticals Inc.

04/03/2025

Oramed Pharmaceuticals Issues Letter to Shareholders

https://mailchi.mp/oramed/oramed-pharmaceuticals-issues-letter-to-shareholders-bfg1a3ws1r $ORMP

CEO Nadav Kidron: "I am happy to take this opportunity to provide our shareholders with an overview of our key accomplishments and outline our future direction."

11/02/2025

Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin - https://mailchi.mp/oramed/oramed-announces-transformative-joint-venture-to-accelerate-development-and-commercialization-of-oral-insulin "We are excited to launch OraTech, a company that brings together Oramed’s technology and clinical development expertise with HTIT’s state-of-the-art manufacturing capabilities," said Nadav Kidron, CEO of Oramed. $ORMP

"We are excited to launch OraTech, a company that brings together Oramed’s technology and clinical development expertise with HTIT’s state-of-the-art manufacturing capabilities," said Nadav Kidron, CEO of Oramed.

07/10/2024

Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt - https://mailchi.mp/oramed/oramed-pharmaceuticals-announces-restructuring-of-scilex-holding-company-debt $ORMP "We believe that this restructuring significantly enhances the potential value of our investment in Scilex," said Nadav Kidron, CEO of Oramed Pharmaceuticals

"We believe that this restructuring significantly enhances the potential value of our investment in Scilex," said CEO Nadav Kidron

26/06/2024

Oramed Letter to Shareholders - https://mailchi.mp/oramed/oramed-letter-to-shareholders-fwwkozy4ih $ORMP

We are pleased to share this letter from the CEO

26/06/2024

Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock - https://mailchi.mp/oramed/oramed-pharmaceuticals-inc-announces-the-buy-back-of-its-common-stock $ORMP

Repurchase plan allowing for the buy-back over the next 12 months

20/02/2024

Oramed Letter to Shareholders - https://mailchi.mp/oramed/oramed-letter-to-shareholders-rle6rx759k We're happy to report that we stand today on solid ground with many opportunities through which we seek to increase shareholder value. $ormp

We're happy to report that we stand today on solid ground with many opportunities through which we seek to increase shareholder value.

23/08/2023

This week we hosted colleagues from HTIT for ongoing discussions on our Joint Venture. We look forward to working together to bring oral insulin to market in China and beyond.

$ORMP

02/08/2023

Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Technology Globally - https://mailchi.mp/oramed/oramed-signs-term-sheet-with-htit-to-create-a-joint-venture-to-advance-technology-globally

The JV would be responsible for developing, marketing and commercializing drug products globally, focusing on Oramed’s oral insulin and POD™ technology, as well as other assets in the Oramed pipeline. The parties intend for the JV to initiate a Phase 3 oral insulin trial in the United States.
$ORMP

Joint Venture to advance registration of oral insulin in the United States and other countries

20/06/2023

Oramed to Present at 83rd American Diabetes Association Conference - https://mailchi.mp/oramed/oramed-to-present-at-83rd-american-diabetes-association-conference
The presentation will include an overview of data from Oramed’s Phase 2 oral insulin trial for the treatment of NASH as well as discuss how oral insulin was found to potentially reduce liver fibrosis and fat in patients with NASH and Type 2 Diabetes.
$ORMP

The presentation will include an overview of data from Oramed’s Phase 2 oral insulin trial for the treatment of NASH as well as discuss how oral insulin was found to potentially reduce liver fibrosis and fat in patients with NASH and Type 2 Diabetes.

18/05/2023

Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit - https://mailchi.mp/oramed/oramed-to-present-at-novel-therapies-for-type-2-diabetes-obesity-summit
Chief Scientific Officer Dr. Miriam Kidron will deliver an in-person presentation at the Summit in Boston, MA, on May 31, 2023. The presentation will include an overview of Oramed’s oral delivery technology as well as insights from the Company’s recent Phase 3 oral insulin clinical trials.

$ORMP

Chief Scientific Officer Dr. Miriam Kidron will deliver an in-person presentation at the Summit in Boston, MA, on May 31, 2023.

15/05/2023

Oramed announces its Chinese partner successfully completed a Phase 3 oral insulin clinical trial and that Oramed has completed an analysis of its U.S.-based Phase 3 oral insulin trial with significant lowering of A1C levels seen in patient subgroups - https://mailchi.mp/oramed/oramed-announces-that-its-chinese-partner-successfully-completed-a-phase-3-oral-insulin-clinical-trial
$ORMP

Oramed has completed an analysis of its U.S.-based Phase 3 oral insulin trial with significant lowering of A1C levels seen in patient subgroups

01/05/2023

Oramed is excited to welcome Ben Shapiro to its Board of Directors.

Ben brings a wealth of experience from across multidisciplinary sectors. Ben Shapiro is a successful entrepreneur and business professional who co-founded The Daily Wire, a successful, industry leading, international media outlet. He is also host of “The Ben Shapiro Show,” a popular podcast, and he is the author of numerous New York Times best-selling books.

“We are excited to welcome Ben onto our Board. Ben’s unique talents and qualifications are expected to bring real value to the current Oramed Board. We are delighted to begin working in earnest with him to build shareholder value,” said Oramed Chief Executive Officer, Nadav Kidron.

​​Mr. Shapiro said, “I believe Oramed is in a unique position to utilize its current capital effectively in ways that will be beneficial to its shareholders, given its skilled management and cash position. I am happy to join Oramed’s Board in what I am sure will be an exciting future for Oramed and its shareholders.”

$ORMP

“We are excited to welcome Ben onto our Board. Ben’s unique talents and qualifications are expected to bring real value to the current Oramed Board. We are delighted to begin working in earnest with him to build shareholder value,” said Oramed Chief Executive Officer, Nadav Kidron.

04/01/2023

Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes - https://mailchi.mp/oramed/oramed-granted-us-combination-therapy-patent-for-oral-glp-1-insulin

“With the topline data for our first Phase 3 oral insulin trial expected soon, we continue to further fortify Oramed’s leading position with respect to intellectual property assets addressing the oral delivery of therapeutic proteins currently only available via injection,” stated Oramed CEO Nadav Kidron.
$ORMP

“With the topline data for our first Phase 3 oral insulin trial expected soon, we continue to further fortify Oramed’s leading position with respect to intellectual property assets addressing the oral delivery of therapeutic proteins currently only available via injection,” stated Oramed CEO N...

21/12/2022

Oramed Letter to Shareholders - https://mailchi.mp/oramed/oramed-letter-to-shareholders-nb2kdbc3ar

The year 2022 was a very strong year for Oramed. The first of our two Phase 3 oral insulin trials completed enrollment and we expect to announce topline results in mid-January 2023. We finished Q3 with a cash balance of $160 million, giving us a long runway through topline results for both of our Phase 3 oral insulin trials and filing for U.S. FDA approval of ORMD-0801, potentially the world’s first oral insulin capsule to reach the market.
$ORMP

Topline Pivotal Phase 3 Oral Insulin Data Expected Mid-January 2023

13/12/2022

Check out the highlight video of Oramed’s recent webinar sharing data from its positive phase 2 clinical trial of oral insulin for with a Key Opinion Leader Discussion on the current treatment landscape.

You can see the entire webinar here: https://www.youtube.com/watch?v=YRYwZlojhwg

$ORMP

29/11/2022

Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism - https://mailchi.mp/oramed/oramed-announces-publication-of-oral-insulin-study-in-peer-reviewed-journal-diabetes-obesity-and-metabolism-kjtg4hfvcm
The article is titled: "Oral Insulin (ORMD-0801) in Type 2 Diabetes Mellitus: Dose-Finding 12-Week Randomized Placebo-Controlled Study" and can be accessed on Oramed's website under Scientific Articles and Abstracts.
$ORMP

The original article titled: Oral Insulin (ORMD-0801) in Type 2 Diabetes Mellitus: Dose-Finding 12-Week Randomized Placebo-Controlled Study

17/11/2022

Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH - https://mailchi.mp/oramed/oramed-announces-additional-positive-safety-and-efficacy-data-from-its-phase-2-clinical-trial-of-ormd-0801-for-nash
The presentation of this new data, including a discussion by key opinion leaders, was featured in a webinar today with a replay available on Oramed’s website under Events and Presentations.

$ORMP

Oral insulin candidate demonstrates consistent trends across key secondary endpoints with reduction of liver fat, liver stiffness and lipids

17/11/2022

Join us in half an hour

Please join us tomorrow for a highlighting data from our clinical trial of oral insulin for NASH

Register here: https://touchconference.zoom.us/webinar/register/WN_dy3jzksKQA6kBKZdT5a0_g

$ORMP